DA Davidson analyst Brent Thielman lowered his price target on NCI Building to $7.50 and kept his Neutral rating in the wake of its completed Ply Germ merger, saying the new entity represents a "significant increase in leverage" and a more concentrated ownership structure. The analyst is also concerned about the elevated economic uncertainty heading into 2019 and the recent evidence of slowing demand in parts of the business combining for a "longer pathway to share price recovery". Thielman intends to monitor NCI Building's "progress around synergy realization, debt reduction, and broader macro trends".